基于肠促胰素治疗的药物比较:GLP-1类似物利拉鲁肽的临床优势

摘要

胰升糖素样肽1(GLP-1)受体激动剂和二肽基肽酶4(DPP-4)抑制剂是基于肠促胰素治疗2型糖尿病的2类药物,GLP-1受体激动剂可直接激活GLP-1受体,而DPP-4抑制剂通过阻止肠促胰素的酶降解间接发挥作用,二者在临床应用方面的比较是研究的热点.一项头对头比较研究表明,与DPP-4抑制剂西格列汀相比,GLP-1类似物利拉鲁肽降糖、减轻体重和改善β细胞功能的作用更为明显,同时患者的治疗满意度更高,在药物经济学上成本效益更优.利拉鲁肽的这些优势为2型糖尿病患者的临床治疗提供了新的理想选择.%Glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4)inhibitors are two classes of incretin-based drugs for type 2 diabetes treatment.GLP-1 receptor agonists can directly activate the GLP-1 receptor while DPP-4 inhibitors act indirectly via preventing incretin enzymatic degradation.The comparison of two classes of drugs in clinical use becomes a hot research topic.A head to head comparison study has shown that,compared with DPP-4 inhibitor sitagliptin,GLP-1 analogue liraglutide shows better blood glucose control,weight loss,and β-cell function improvement,as well as higher patient treatment satisfaction and better cost-effectiveness of drug economics.Those advantages of liraglutide provide an ideal choice for the clinical treatment of patients with type 2 diabetes.